In briefBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c4529 (Published 18 August 2010) Cite this as: BMJ 2010;341:c4529
NICE rules out asthma drug: The UK National Institute for Health and Clinical Excellence has ruled out omalizumab (Xolair) for severe persistent allergic asthma in children aged 6-11 years. In new draft guidance NICE said that it offered little extra benefit over existing treatments so was not an effective use of NHS resources (www.nice.org.uk/guidance/index.jsp?action=folder&o=50292). Children currently taking it should have the opportunity to continue treatment until it is considered appropriate to stop. Appeals against the guidance must be submitted by 26 August. Final guidance is expected in September. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial